

Info Sheet for Technical description

No. XXXX (事務局付番)

Organization

* Mandatoty fields

| | | |
|--|--|--|
| Name of Organization* | C4U Corporation | |
| Address, City, States, Zip, Country* | Yamadaoka 2-8, Suita, Osaka, 565-0871, JAPAN | |
| URL | https://www.crispr4u.jp/en/ | |
| Brief Descriptions of Organization* (Approx. 100 words) | C4U is a biotechnology venture company from Osaka University, engaging in research and development of novel genome editing technology, CRISPR-Cas3. Utilizing newly invented cutting-edge genome editing technology, C4U promotes the development of new treatments for various diseases, including genetic diseases. C4U also collaborates with other companies and is working to develop platforms for applications in other industries. | |
| Contact address | Name* | Katsu Akiyama / Kohei Kishi |
| | Department* / Position | Business Development Div. |
| | E-mail* / TEL | akiyama@crispr4u.com / +81-80-4651-3645 k.kishi@crispr4u.com / +81-80-4384-9466 |

What kind of technology do you want to offer? *

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

| Options* | Comments |
|---|----------|
| <input checked="" type="checkbox"/> Yes | |
| <input type="checkbox"/> No | |

Filled in by*

Date*

| |
|--------------------|
| Katsuyoshi Akiyama |
| 2023/9/7 |

Sheet [C] Platform Technologies *that are not included in Group B***Info Sheet for Technical overview**

No. XXXX (事務局付番)

* Mandatoty fields

Title***Nobel gene editing platform – CRISPR-Cas3 – by C4U Corporation****Description***

C4U Corporation (“C4U”) owns a proprietary platform named CRISPR-Cas3, which is one of the gene editing technologies and has different profiles from well-known CRISPR-Cas9 as below.

- 1) Cas3 patent families are independent from Cas9 patents and there is no umbrella patent between Cas3 and Cas9, and C4U has exclusively in-licensed Cas3 patents from Osaka University;
- 2) Off-target (undesired) deletion is undetectable because recognition size by crRNA (gRNA) is longer; and
- 3) Larger portion of gene is deleted while Cas9 has a point cut ability.

These unique profiles can differentiate Cas3 platform from other gene editing technologies and it can be used not only for treatment and diagnostics in healthcare industry but also for agriculture and fishery industries.

C4U is looking for a global and regional partner who would like to utilize our Cas3 into their research program and platform to generate pipeline products.

Filled in by*

Kohei Kishi

Date*

7-Sep-23